Incubate’s John Stanford on why MFN is voluntary in name only — and why the moonshot is the first casualty of drug pricing pressure.
News|Articles|March 17, 2026
Understanding distribution models through prescription capture patterns
This insight piece breaks down how three different specialty pharmacy network structures relate to prescription capture patterns in medically integrated dispensing settings. You’ll learn what distinguishes each type of limited distribution model, how those differences are seen in internal vs. external dispensing behavior, and what the data suggests about the way prescriptions flow across networks. It’s designed to help teams better understand distribution models and think more clearly about how network design may shape dispensing dynamics.
Related to this article
FDA grants Ultomiris accelerated approval for primary immunoglobulin A nephropathy, a pharma funding roundup covers Alcon’s $550 million acquisition of Neurotech and AI Proteins’ collaboration with Astellas, and Incubate’s John Stanford on which therapeutic areas MFN deals might hit hardest.
Alcon is acquiring Neurotech Pharmaceuticals to add the only FDA-approved MacTel cell therapy to its retina portfolio, while AI Proteins has enters a collaboration with Astellas to design novel miniprotein therapeutics.
FDA has granted accelerated approval to Ultomiris based on Phase III data showing a 43.4% placebo-adjusted reduction at 34 weeks.
A new ICER and West Health report finds median drug launch prices climbed to $257,000, the FDA approves GSK’s Hibsago as the first functional-cure therapy for chronic hepatitis B, and CSL names Deborah Waterhouse as CEO and managing director.
Median Drug Launch Prices Hit $257,000 as Access Barriers Persist, ICER and West Health Report Finds
Median net launch prices for new drugs climbed between 2022 and 2025 to $257,000, according to a new ICER and West Health report that also found persistent coverage and access barriers for patients.
The FDA approved GSK's bepirovirsen for adults with chronic hepatitis B on nucleoside therapy, based on phase 3 trials showing 19% functional cure.
Deborah Waterhouse is leaving ViiV Healthcare to become CEO and managing director of CSL.
Trending on PharmExec
1
FDA Grants Ultomiris Accelerated Approval in the U.S. for Adults with Primary Immunoglobulin A Nephropathy
2
FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B
3
Roundup: Alcon Acquires Neurotech and Encelto, Ai Proteins Enters Research Collaboration and License Agreement with Astellas Pharma
4
Pharmaceutical Executive Daily: FDA Grants Ultomiris Accelerated Approval in the U.S.
5